Kashiv BioSciences, a vertically integrated biopharmaceutical company, has announced an exclusive licensing and supply agreement with Intas Pharmaceuticals Ltd for the commercialization of a complex peptide product across Europe, the United Kingdom, and India.
Kashiv BioSciences stated that the complex peptide product will be commercialized by Intas in India and by its subsidiary, Accord Healthcare Ltd, in Europe and the UK.
Kashiv BioSciences Agreement Covers Europe, UK, and India Markets
Under the agreement, Kashiv BioSciences will be responsible for regulatory registration, manufacturing, and supply of the product.
Accord will manage commercialization and distribution across the European, UK, and Indian markets.
Also Read: Regenerative Medicine Startup Pandorum Technologies Raises $18 Million Series B
The partnership is aimed at expanding access to therapies across these regions while strengthening the participating companies’ pharmaceutical portfolios.
“Our partnership with Intas, leveraging its strong pan-European presence through Accord, enables Kashiv to expand our commercial reach across key European, UK, and Indian markets and strengthen our overall portfolio in the regions,” said Dr Sandeep Athalye, Global CEO of Kashiv BioSciences.
“This collaboration reflects our shared commitment to improving patient outcomes and aligns with our mission to make high-quality, affordable therapies more accessible for patients worldwide.”
“We are pleased to partner with Kashiv BioSciences to expand access to high-quality therapies across Europe, the UK and India.
By combining our capabilities, we aim to strengthen our presence and better serve the unmet needs of patients and healthcare professionals,” said Binish Chudgar, Chairman and Managing Director of Intas Pharmaceuticals.
